Using the breast cancer cell lines sensitive or resistant to palbociclib, it was showed that the complex change of Rb1 pathway was related to resistance to CDK4/6 inhibitor, Rb1 deficient in function is an important factor that contributes to palbociclib and abemaciclib resistance in breast cancer patients (18, 19). Here, RB1 is linked to breast cancer.